glp 1 ra drugs list What to know about the new era of GLP-1 Mapping the effectiveness and risks
Description
Both medications contain the same active ingredient but are approved for different primary indications and at different doses
Available from: Cited 12/8/2025
It was found that more patients in the LIR group than the placebo group maintained their weight loss by 5%, which indicated that LIR 3.0 mg/d is expected to improve the maintenance of weight loss (93)
A.MentzR
Our findings indicate that patients treated with semaglutide, particularly at higher doses such as Wegovy (2.4 mg), exhibited a higher incidence of psychiatric outcomes compared to non-GLP-1 RA users
